The published protocol covers 44 people with alcohol use disorder and 44 healthy volunteers, tracking dopamine and craving. No results yet, only the design.
Recap by typeshit. Full story at Bioengineer.org.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
Mounjaro brought in $10.7 billion and Zepbound $5.4 billion. Lilly says about seven in 10 Medicare Bridge patients use its drugs, while Foundayo hit $184 million.
Loading…